Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
LAUSANNE, Switzerland, March 19 /PRNewswire/ --
Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has received clearance from the U.S. Federal Trade Commission, through the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, for its proposed acquisition of CollaGenex (Nasdaq: CGPI).
"We are pleased with the quick and orderly review of our proposal by the Federal Trade Commission and are confident in our ability to complete this…